<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="308122">
  <stage>Registered</stage>
  <submitdate>2/07/2009</submitdate>
  <approvaldate>29/07/2009</approvaldate>
  <actrnumber>ACTRN12609000632291</actrnumber>
  <trial_identification>
    <studytitle>The effect of intravenous fish oil on the electrical properties of the human atria in patients undergoing elective electrophysiological evaluation and /or radiofrequency ablation of suraventricular or ventricular tachycardia</studytitle>
    <scientifictitle>The effect of intravenous fish oil on the electrical properties of the human atria in patients undergoing elective electrophysiological evaluation and /or radiofrequency ablation of suraventricular or ventricular tachycardia.</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Cardiac electrophysiology</healthcondition>
    <healthcondition>Human atrial electrical properties.</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Normal development and function of the cardiovascular system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Intravenous fish oil.Participants will given  a single dose of 100ml/10g (fish oil) of Omegaven . It will be mixed with 250ml 20% intralipid and infused at a rate of 0.5ml/kg/hr</interventions>
    <comparator>Placebo is  an intravenous infusion of 250 ml 20% Intralipid  given as a single dose over 4hrs .</comparator>
    <control>Placebo</control>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change in atrial electrical conduction times .</outcome>
      <timepoint>As measured during study protocol.Electrophysiological evaluation will consist of :
 Measurement of atrial refractory periods (ERPs) - conducted from three sites distal coronary sinus, right atrial appendage and proximal coronary sinus and at three pacing cycle lengths 600ms, 500ms 400ms using 10ms increments from below refractoriness ( commencing at 150ms).
 P wave duration in sinus rhythm .
 Atrial conduction times measured at two sites along the coronary sinus(cs) by pacing from the distal bipole of the  cs and measuring time to activation at the proximal bipole and at the right atrial appendage pacing the distal bipole from the cs catheter measuring time to activation at distal bipole from a catheter positioned at the right atrial appendage . these times will be measureed at pacing cycle lengths of 600, 500 and 400ms. 
Conduction delay at the crista terminalis (ct) which will be assessed during pacing from the distal cs and mid right atrium at cycle lengths of 600,500and 400ms .Conduction delay at the ct will be analyzed by the timing between double potentials at the ct.
Sinus node function. This will be assessed by rapid atrial pacing at cycle lengths of 400 and 400ms to determine corrected sinus node recovery time.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Prevention of induction of atrial fibrillation during rapid atrial pacing</outcome>
      <timepoint>Will consist of atrial pacing at a cycle length of 200ms for 10 seconds at 20mA 10 times during the electrophysiological study.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Participants recruited from  patients undergoing elective electrophysiological evaluation and or radiofrequency ablation of supraventricular or ventricular tachycardia.
They may or may not have impaired ventricular function.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Use of Amiodarone in the previous 6 months.
Patients with known allergies to fish or egg protein</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Educational / counselling / training</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Participants will be recruited from patients undergoing elective electrophysiological evaluation and or radiofrequency ablation for suraventricular or ventricular tachycardia. They have been placed on a hospital waiting list . Approx 50% will come from the hospital outpatient cardiology clinic and 50% from the principal Cardiologists rooms . From  the hospital waiting list participants will be  approached by either the princial investigater or assistant  to establish interest or not.Mostly this will be done over the phone  and where approprate the relevant paperwork forwarded.
With regard to randomisation. The study will have two groups . Those who receive fish oil and those who do not . Participants will be randomly allocated to receive fish oil or not using sequentially numbered opaque sealed envelopes.</concealment>
    <sequence>Simple randomisation using sequentially numbered opaque sealed envelopes.</sequence>
    <masking />
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/10/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>40</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>3050</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Royal Melbourne Hospital</primarysponsorname>
    <primarysponsoraddress>Grattan St 
Parkville,  VICTORIA  3050</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>Cardiac electrophysiology (EP): Paul Sparks</fundingname>
      <fundingaddress>Royal Melbourne Hospital
Grattan St 
Parkville  VIC  3050</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Royal Melbourne Hospital</fundingname>
      <fundingaddress>Grattan St 
Parkville, VICTORIA   3050</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>To observe the effects of intravenous fish oil on the electrophysiological properties of the human atria</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Human Research  and Ethics Committee (HREC) Office for Research Royal Melbourne Hospital</ethicname>
      <ethicaddress>Level 6 East Main Block
Royal Melbourne Hospital
Grattan St   Parkville  VIC  3050</ethicaddress>
      <ethicapprovaldate />
      <hrec>2009.076</hrec>
      <ethicsubmitdate>23/04/2009</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Fiona Sutherland</name>
      <address>Cardiology Dept
The Royal Melbourne Hospital
Grattan St
Parkville    Vic   3050</address>
      <phone>+61 393427133</phone>
      <fax>+61 393472808</fax>
      <email>fiona.sutherland@mh.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Fiona Sutherland</name>
      <address>Cardiology Dept
The Royal Melbourne Hospital
Grattan St
Parkville    Vic   3050</address>
      <phone>+61 393427133</phone>
      <fax>+61 393472808</fax>
      <email>fiona.sutherland@mh.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Fiona Sutherland</name>
      <address>Cardiology Dept
The Royal Melbourne Hospital
Grattan St
Parkville    Vic   3050</address>
      <phone>+61 393427133</phone>
      <fax>+61 393472808</fax>
      <email>fiona.sutherland@mh.org.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>